Leukocyte migration inhibition assay in patients with bladder cancer.
The leukocyte migration inhibition assay has demonstrated successfully tumor-associated antigenic activity in protein extracts of cell culture lines of a number of neoplasms. Our data have shown a high degree of leukocyte migration inhibition reactivity with protein extracts from the well characterized T-24 transitional carcinoma cell line. Thus, the leukocyte migration inhibition assay may prove a valuable method of in vitro assessment of the cell-mediated immunity of bladder cancer patients and as a method to monitor attempts at further purification of tumor-associated antigens.
D000951:Antigens, Neoplasm; D002295:Carcinoma, Transitional Cell / Q000276:immunology*; D002460:Cell Line; D002464:Cell Migration Inhibition; D006801:Humans; D007111:Immunity, Cellular; D007962:Leukocytes / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology*
D000951:Antigens, Neoplasm